# Bright Minds Biosciences Inc.: financial statements, quarterly

DRUG · Nasdaq · CIK 1827401 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/drug.md) · [Financials](/companies/drug/financials.md) · [Filings](/companies/drug/filings.md) · [Insiders](/companies/drug/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/drug/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2018-09-30) | period not labelled (2019-05-31) | period not labelled (2019-09-30) | period not labelled (2020-09-30) | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.0](/filings/0001062993-22-001182.md) | not reported | [0.1](/filings/0001062993-22-024547.md) | [0.8](/filings/0001062993-23-023281.md) | [19.8](/filings/0001062993-24-021301.md) | [11.6](/filings/0001062993-24-021301.md) | [6.7](/filings/0001062993-24-021301.md) | [5.7](/filings/0001062993-24-021301.md) |
| Current assets | $m | not reported | not reported | not reported | [0.9](/filings/0001062993-22-001182.md) | [20.0](/filings/0001062993-22-024547.md) | [11.9](/filings/0001062993-23-023281.md) | [6.8](/filings/0001062993-24-021301.md) | [6.0](/filings/0001062993-24-021301.md) |
| Total assets | $m | not reported | not reported | not reported | [0.9](/filings/0001062993-22-001182.md) | [20.0](/filings/0001062993-22-024547.md) | [12.1](/filings/0001062993-23-023281.md) | [6.9](/filings/0001062993-24-021301.md) | [6.1](/filings/0001062993-24-021301.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | [0.6](/filings/0001062993-22-024547.md) | [1.5](/filings/0001062993-23-023281.md) | [0.3](/filings/0001062993-24-021301.md) | [0.5](/filings/0001062993-24-021301.md) |
| Total liabilities | $m | not reported | not reported | not reported | [0.2](/filings/0001062993-22-001182.md) | [0.6](/filings/0001062993-22-024547.md) | [1.5](/filings/0001062993-23-023281.md) | [0.3](/filings/0001062993-24-021301.md) | [0.6](/filings/0001062993-24-021301.md) |
| Shareholders' equity | $m | not reported | [0.0](/filings/0001062993-22-001182.md) | [0.0](/filings/0001062993-22-024547.md) | [0.7](/filings/0001062993-23-023281.md) | [19.4](/filings/0001062993-24-021301.md) | [10.5](/filings/0001062993-24-021301.md) | [6.6](/filings/0001062993-24-021301.md) | [5.5](/filings/0001062993-24-021301.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Total liabilities: ifrs-full:Liabilities
- Shareholders' equity: ifrs-full:Equity

Shares outstanding: 4,524,087 at 2024-09-30, from the cover of the [20-F filed 2024-12-31](/filings/0001062993-24-021301.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.